Big pharmas need to collaborate to boost declining R&D returns
This article was originally published in Scrip
Executive Summary
Research heads in big pharma companies need to look at how to improve the return on investment of the R&D budgets if they are going to maintain their share of company spending. In its annual review of the R&D returns of the leading 12 pharma companies, Deloitte, the international professional services company, concludes that the industry needs to take a more innovative approach through collaborations if it is to deliver improved R&D returns.